Program Related Investment
Stingray Therapeutics
First generation immune-oncology therapies are in adaptive immunity. They modify T-cells or block adaptive immunity suppressive proteins (called ‘checkpoints’). These therapies have made great strides, but resistance is increasing and many tumors do not respond, including life threatening children’s tumors like medulloblastoma. We are an immune oncology company focused on adding innate immunity into the fight against cancers. This should allow for more durable cures and many more kinds of tumors responding. Our oral medicine stimulates innate immunity, and will likely be used with adaptive immunity modulators – enabling both arms of the immune system together to fight cancer. It is expected to treat many types of cancers – prolonging life for far more patients.
